Theravance Biopharma, Inc. Accumulated Other Comprehensive Income
Theravance Biopharma, Inc. (TBPH) had Accumulated Other Comprehensive Income of -$76.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-11
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$76.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$62.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $61.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $32.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$76.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$62.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $61.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $32.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$10.00K 10-Q · filed 2025-08-13 |
| 2024-12-31 | $7.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $50.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$22.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$41.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$65.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | -$225.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$286.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $51.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$15.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$121.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$45.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$28.00K 10-Q · filed 2022-05-06 |
| 2021-09-30 | $14.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $8.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $17.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $47.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $122.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $280.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $512.00K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $145.00K 10-K · filed 2021-02-26 |
| 2019-09-30 | $94.00K 10-Q · filed 2019-11-08 |
| 2019-06-30 | $129.00K 10-Q · filed 2019-08-05 |
| 2019-03-31 | -$36.00K 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$166.00K 10-K · filed 2020-02-27 |
| 2018-09-30 | -$331.00K 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$525.00K 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$854.00K 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$733.00K 10-K · filed 2019-02-28 |
| 2017-09-30 | -$292.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$248.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$272.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$253.00K 10-K · filed 2018-02-28 |
| 2016-09-30 | $39.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $181.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $126.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$70.00K 10-K · filed 2017-03-01 |
| 2015-09-30 | $43.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $25.00K 10-Q · filed 2015-08-13 |
| 2015-03-31 | $31.00K 10-Q · filed 2015-05-13 |
| 2014-12-31 | -$82.00K 10-K · filed 2016-03-11 |
| 2014-09-30 | -$27.00K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $70.00K 10-Q · filed 2014-08-14 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |